Scott Thomas Smith

CFO Scott Thomas Smith purchases 100 ASND shares at $219.00; stock down 10.5% in 30 days

CFO Scott Thomas Smith acquired 100 shares of Ascendis Pharma at $219.00 on 2026-06-02, increasing his holdings from 4,267 to 4,367 shares. The transaction occurred as the stock has declined 10.5% over the past 30 days and is trading 13.0% below its 52-week high of $250.74. This modest insider buy by a senior financial officer may indicate comfort with the current valuation, though the modest share count—a 2.3% increase in his holdings—and the broader recent price weakness suggest this is not a material accumulation signal.

CFO Scott Thomas Smith purchases 250 ASND shares at $223.32; stock now -13.0% from 52-week high

Scott Thomas Smith, EVP & Chief Financial Officer, purchased 250 shares at $223.32 on 2026-05-29, increasing his holdings from 4,017 to 4,267 shares (a +6.2% increase). The current price of $218.06 represents a -13.0% decline from the 52-week high of $250.74, and the stock has fallen -10.5% over the prior 30 days. The transaction occurred as the stock faced downward momentum across both the recent month and quarter (-3.5% over 90 days), providing context for an insider purchase at a depressed price level relative to recent peaks.